Table 3.

Multivariate analysis of response rates to third-line chemotherapy

Clinical factors	No. of patients	Response rate (95% CI)	P value
Age
<60	35	52.6% (30.1–75.0%)	0.50
≥60	19	44.0% (23.7–56.2%)
PS
0.1	28	57.1% (38.8–75.4%)	0.04
2.3	26	30.7% (13.0–48.5%)
Pathology
Mucinous/clear cell	6	33.3% (4.3–71.0%)	0.22
Non-mucinous/clear cell	48	45.8% (31.7–59.9%)
No. of target lesions
1	40	45.0% (29.5–60.4%)	0.37
2.3	14	42.8% (16.9–68.7%)
Primary DFI
<6 months	17	17.6% (0.4–35.7%)	0.009
≥6 months	37	51.3% (35.2–67.4%)
Secondary DFI
<6 months	33	42.4% (25.5–59.2%)	0.70
≥6 months	21	47.6% (26.2–68.9%)
Response to second-line therapy
Responders	35	45.7% (29.2–62.2%)	0.09
Non-responders	19	31.5% (10.6–52.4%)
PT regimens
PT regimens	36	38.8% (22.9–54.8%)	0.75
Non-PT regimens	18	44.4% (21.4–67.4%)

PT Platinum/taxane